Circulating tumor cells in patients with breast cancer dormancy
S Meng, D Tripathy, EP Frenkel, S Shete… - Clinical cancer …, 2004 - AACR
S Meng, D Tripathy, EP Frenkel, S Shete, EZ Naftalis, JF Huth, PD Beitsch, M Leitch…
Clinical cancer research, 2004•AACRPurpose: The purpose of this study was to test the hypothesis that circulating tumor cells
(CTCs) are present in patients many years after mastectomy without evidence of disease
and that these CTCs are shed from persisting tumor in patients with breast cancer dormancy.
Experimental Design: We searched for CTCs in 36 dormancy candidate patients and 26 age-
matched controls using stringent criteria for cytomorphology, immunophenotype, and
aneusomy. Results: Thirteen of 36 dormancy candidates, 7 to 22 years after mastectomy and …
(CTCs) are present in patients many years after mastectomy without evidence of disease
and that these CTCs are shed from persisting tumor in patients with breast cancer dormancy.
Experimental Design: We searched for CTCs in 36 dormancy candidate patients and 26 age-
matched controls using stringent criteria for cytomorphology, immunophenotype, and
aneusomy. Results: Thirteen of 36 dormancy candidates, 7 to 22 years after mastectomy and …
Abstract
Purpose: The purpose of this study was to test the hypothesis that circulating tumor cells (CTCs) are present in patients many years after mastectomy without evidence of disease and that these CTCs are shed from persisting tumor in patients with breast cancer dormancy.
Experimental Design: We searched for CTCs in 36 dormancy candidate patients and 26 age-matched controls using stringent criteria for cytomorphology, immunophenotype, and aneusomy.
Results: Thirteen of 36 dormancy candidates, 7 to 22 years after mastectomy and without evidence of clinical disease, had CTCs, usually on more than one occasion. Only 1 of 26 controls had a possible CTC (no aneusomy). The statistical difference of these two distributions was significant (exact P = 0.0043). The CTCs in patients whose primary breast cancer was just removed had a half-life measured in 1 to 2.4 hours.
Conclusions: The CTCs that are dying must be replenished every few hours by replicating tumor cells somewhere in the tissues. Hence, there appears to be a balance between tumor replication and cell death for as long as 22 years in dormancy candidates. We conclude that this is one mechanism underlying tumor dormancy.
AACR